NTHU
19.2.2020 10:02:05 CET | Business Wire | Press release
A research team led by Professor Hsueh-Shih (Sean) Chen of National Tsing Hua University has recently announced that they have developed a new quantum dot material which is more stable and provides more realistic color. The main limitations of the current quantum dot display materials is that they are unstable and easily damaged, and the team has rectified this by growing “shield” with approximately 1-nanometer at the crystal facets of each quantum dot. The new material has a wide range of applications, including the screens used in televisions, computers, mobile phones, and cameras.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200219005017/en/
With the support of NTHU, the team has already applied for patents for the new material and has established the HsinLight Inc. to produce it on a commercial scale. It is expected that the first quantum dot screens will begin production in 2020.
Most of the displays currently on the market are liquid crystal displays (LCD), which have a color gradation and saturation and can only display about one third of the colors visible to the human eye, and even the so-called “retinal grade” OLED displays used in such devices as iPhone 11 can only display about half of the colors visible to the human eye. Displays equipped with new QD material (QLED TV) will display nearly 90% of the colors visible to the human eye.
However, there are still a few challenges to be overcome before quantum dot material goes into widespread use. Chen explained that quantum dots are spherical crystals of about three nanometers in size, and are easily damaged by water and oxygeny molecules, which diminishes their luminosity. At present, major manufacturers such as Samsung control this problem by sandwiching the quantum dots in a layer of protective film, but it’s not cost-effective and easily lose the protective function if there is a small pin hole.
Inspired by the shield used by the comic book superhero Captain America in the Avengers series, Chen hit upon the idea of giving each quantum dot its own shields about one nanometer in size, which effectively resists water and oxidation and also increases material stability and the display’s lifespan.
In the past two years several companies have begun selling televisions with quantum dot technology, but due to the fragile nature of quantum materials, they are difficult to mass produce, and the price is relatively high. However, using Chen’s unique shield technology to protect the quantum dots will significantly reduce production costs.
A typical 55-inch quantum dot screen consists of more than 100 million trillion (10 to the 20th power) quantum crystals, and Chen's research team has developed a technique for precisely controlling the size of each quantum dot, so that each quantum crystal differs in size by no more than 0.5 nanometers. Precisely controlling the size of the quantum dots and shields allows them to accurately emit blue, green, yellow, orange, red, infrared, and other colors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200219005017/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
